Cargando…

Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib

Data on the effect of ruxolitinib on antibody response to severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccination in patients with myeloproliferative neoplasms (MPN) is lacking. We prospectively evaluated anti-spike-receptor binding domain antibody (anti-S Ab) levels after the second dose of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeda, Daisuke, Terao, Toshiki, Miura, Daisuke, Narita, Kentaro, Fukumoto, Ami, Kuzume, Ayumi, Kamura, Yuya, Tabata, Rikako, Tsushima, Takafumi, Takeuchi, Masami, Hosoki, Takaaki, Matsue, Kosei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990027/ https://www.ncbi.nlm.nih.gov/pubmed/35402455 http://dx.doi.org/10.3389/fmed.2022.826537

Ejemplares similares

Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
por: Tsushima, Takafumi, et al.
Publicado: (2022)

Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
por: Ikeda, Daisuke, et al.
Publicado: (2022)

Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
por: Narita, Kentaro, et al.
Publicado: (2021)

Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myeloma
por: Terao, Toshiki, et al.
Publicado: (2021)

Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
por: Terao, Toshiki, et al.
Publicado: (2022)

Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide
por: Terao, Toshiki, et al.
Publicado: (2021)

Antibody response to COVID-19 vaccination in patients with lymphoma
por: Narita, Kentaro, et al.
Publicado: (2022)

P1547: CLINICAL CHARACTERISTICS OF PATIENTS WITH PROLONGED VIRAL SHEDDING OF OMICRON VARIANT IN HAEMATOLOGICAL DISEASE
por: Ikeda, Daisuke, et al.
Publicado: (2023)

P1137: COMBINED METABOLIC HETEROGENEITY AND TOTAL LESION GLYCOLYSIS FROM PET-CT IMPROVES THE PROGNOSTIC STRATIFICATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
por: Ikeda, Daisuke, et al.
Publicado: (2023)

Social frailty predicts worse outcomes in patients with multiple myeloma: A novelty in an old approach
por: Terao, Toshiki, et al.
Publicado: (2020)

Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease
por: Ikeda, Daisuke, et al.
Publicado: (2023)

Light chain deposition disease involving kidney and liver in a patient with IgD myeloma
por: Tsushima, Takafumi, et al.
Publicado: (2021)

Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort Study
por: Narita, Kentaro, et al.
Publicado: (2023)

Baseline total lesion glycolysis combined with interim positron emission tomography‐computed tomography is a robust predictor of outcome in patients with peripheral T‐cell lymphoma
por: Kitadate, Akihiro, et al.
Publicado: (2020)

Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma
por: Kobayashi, Hiroki, et al.
Publicado: (2020)

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence
por: Kitadate, Akihiro, et al.
Publicado: (2021)

Brain toxoplasmosis after HLA haploidentical transplantation for acute myeloid leukemia
por: Tsushima, Takafumi, et al.
Publicado: (2022)

Fatal thrombotic microangiopathy with rhabdomyolysis as an initial symptom after the first dose of mRNA–1273 vaccine: A case report
por: Kamura, Yuya, et al.
Publicado: (2022)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
por: Eliaçık, Eylem, et al.
Publicado: (2015)

Kidney involvement of chronic active Epstein‐Barr virus infection
por: Fukumoto, Ami, et al.
Publicado: (2023)

Severe rhabdomyolysis and SARS-CoV-2 vaccination: a reply to the letter by Dr. Josef Finsterer.: Reply to Letter to the Editor regarding our report to Dr. Finsterer.
por: Kamura, Yuya, et al.
Publicado: (2022)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years
por: Matsue, Kosei, et al.
Publicado: (2019)

Bone marrow infiltration pattern in patients with intravascular large B‐cell lymphoma diagnosed by random skin biopsy
por: Matsue, Kosei, et al.
Publicado: (2020)

Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?
por: Caocci, Giovanni, et al.
Publicado: (2021)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
por: Tremblay, Douglas, et al.
Publicado: (2019)

Immune response to SARS-CoV-2 vaccination among renal replacement therapy patients with CKD: a single-center study
por: Matsunami, Masatoshi, et al.
Publicado: (2021)

N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma
por: Abe, Yoshiaki, et al.
Publicado: (2019)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis
por: te Linde, Elsemieke, et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis
por: Caocci, Giovanni, et al.
Publicado: (2021)

Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma
por: Suehara, Yasuhito, et al.
Publicado: (2017)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
por: Gupta, Vikas, et al.
Publicado: (2020)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Anti-Sars-Cov-2 Antibody and T-Cell Responses Using Deep T-Cell Receptor Immunosequencing after Vaccination Among Healthy Individuals and Patients with Multiple Myeloma or Lymphoma
por: Takamatsu, Hiroyuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_76saieajhb4qhh6o1qbj2mgn5g